1. Home
  2. PMAX vs CALC Comparison

PMAX vs CALC Comparison

Compare PMAX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

N/A

Current Price

$2.29

Market Cap

4.5M

Sector

N/A

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$5.04

Market Cap

63.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMAX
CALC
Founded
2019
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
63.0M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
PMAX
CALC
Price
$2.29
$5.04
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
1.7M
132.5K
Earning Date
09-23-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,799,100.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$1.42
52 Week High
$24.36
$5.34

Technical Indicators

Market Signals
Indicator
PMAX
CALC
Relative Strength Index (RSI) 48.95 65.93
Support Level $2.30 $4.24
Resistance Level $2.97 $5.34
Average True Range (ATR) 0.36 0.41
MACD -0.02 0.04
Stochastic Oscillator 37.65 73.24

Price Performance

Historical Comparison
PMAX
CALC

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: